Biomedical Engineering Reference
In-Depth Information
68. Haider AS, Lowes MA, Gardner H, Bandaru R, Darabi K,
Chamian F, et al. (2007) Novel insight into the agonistic
mechanism of alefacept in vivo: differentially expressed
genes may serve as biomarkers of response in psoriasis
patients. J. Immunol. 178, 7442-7449.
69. Heffernan MP, Leonardi CL. (2010) Alefacept for psoriasis.
Semin. Cutan. Med. Surg. 29, 53-55.
70. Krueger GG. (2003) Clinical response to alefacept: results of
a phase 3 study of intravenous administration of alefacept in
patients with chronic plaque psoriasis. J. Eur. Acad. Derma-
tol. Venereol. 17(Suppl. 2), 17-24.
71. Krueger GG, Gottlieb AB, Sterry W, Korman N, Van De
Kerkhof P. (2008) A multicenter, open-label study of repeat
courses of intramuscular alefacept in combination with other
psoriasis therapies in patients with chronic plaque psoriasis.
J. Dermatolog. Treat. 19, 146-155.
72. Scheinfeld N. (2007) Alefacept: its safety profile, off-label
uses, and potential as part of combination therapies for
psoriasis. J. Dermatolog. Treat. 18, 197-208.
73. Strober BE, Menon K. (2007) Alefacept for the treatment of
psoriasis and other dermatologic diseases. Dermatol. Ther.
20, 270-276.
74. Linsley PS, Wallace PM, Johnson J, Gibson MG, Greene JL,
Ledbetter JA, et al. (1992) Immunosuppression in vivo by a
soluble form of the CTLA-4 T cell activation molecule.
Science 257, 792-795.
75. Korhonen R, Moilanen E. (2009) Abatacept, a novel
CD80/86-CD28 T cell co-stimulation modulator, in the treat-
ment of rheumatoid arthritis. Basic Clin. Pharmacol. Toxicol.
104, 276-284.
76. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva
CA, et al. (2010) Long-term safety and efficacy of abatacept
in children with juvenile idiopathic arthritis. Arthritis Rheum.
62, 1792-1802.
77. Ruperto N, Lovell DJ, Quartier P, Paz E, Rubio-Perez N, Silva
CA, et al. (2008) Abatacept in children with juvenile
idiopathic arthritis: a randomised, double-blind, placebo-
controlled withdrawal trial. Lancet 372, 383-391.
78. Larsen CP, Pearson TC, Adams AB, Tso P, Shirasugi N,
Strobert E, et al. (2005) Rational development of LEA29Y
(belatacept), a high-affinity variant of CTLA4-Ig with
potent immunosuppressive properties. Am.J.Transplant.
5, 443-453.
79. Pearsall RS, Canalis E, Cornwall-Brady M, Underwood KW,
Haigis B, Ucran J, et al. (2008) A soluble activin type IIA
receptor induces bone formation and improves skeletal integ-
rity. Proc. Natl. Acad. Sci. USA 105, 7082-7087.
80. Lotinun S, Pearsall RS, Davies MV, Marvell TH, Monnell TE,
Ucran J, et al. (2010) A soluble activin receptor type IIA
fusion protein (ACE-011) increases bone mass via a dual
anabolic-antiresorptive effect in Cynomolgus monkeys. Bone
46, 1082-1088.
81. Souza TA, Chen X, GuoY, Sava P, Zhang J, Hill JJ, et al. (2008)
Proteomic identification and functional validation of activins
and bone morphogenetic protein 11 as candidate novel muscle
mass regulators. Mol. Endocrinol. 22, 2689-2702.
82. Ruckle J, Jacobs M, Kramer W, Pearsall AE, Kumar R,
Underwood KW, et al. (2009) Single-dose, randomized,
double-blind, placebo-controlled study of ACE-011
(ActRIIA-IgG1) in postmenopausal women. J. Bone Miner.
Res. 24, 744-752.
83. Raje N, Vallet S. (2011) Sotatercept, a soluble activin receptor
type 2A IgG-Fc fusion protein for the treatment of anemia and
bone loss. Curr. Opin. Mol. Ther. 12, 586-597.
84. Cadena SM, Tomkinson KN, Monnell TE, Spaits MS, Kumar
R, Underwood KW, et al. (2010) Administration of a soluble
activin type IIB receptor promotes skeletal muscle growth
independent of fiber type. J. Appl. Physiol. 109, 635-642.
85. Sako D, Grinberg AV, Liu J, Davies MV, Castonguay R,
Maniatis S, et al. (2010) Characterization of the ligand
binding functionality of the extracellular domain of activin
receptor type IIb. J. Biol. Chem. 285, 21037-21048.
86. Cunha SI, Pardali E, Thorikay M, Anderberg C, Hawinkels L,
Goumans MJ, et al. (2010) Genetic and pharmacological
targeting of activin receptor-like kinase 1 impairs tumor
growth and angiogenesis. J. Exp. Med. 207, 85-100.
87. Mitchell D, Pobre EG, Mulivor AW, Grinberg AV, Caston-
guay R, Monnell TE, et al. (2010) ALK1-Fc inhibits multiple
mediators of angiogenesis and suppresses tumor growth. Mol.
Cancer Ther. 9, 379-388.
88. Baldassare A, Fiechtner J, Filipowicz-Sosnowska A, Jeka S,
O'Gorman J, Weaver M, et al. (2007) Preliminary Safety and
Efficacy of LT
b
R-Ig (BG9924) in the Treatment of Rheuma-
toid Arthritis (RA), in American College of Rheumatology,
p. S394.
89. Crowe PD, VanArsdale TL, Walter BN, Ware CF, Hession C,
Ehrenfels B, et al. (1994) A lymphotoxin-beta-specific recep-
tor. Science 264, 707-710.
90. Mauri DN, Ebner R, Montgomery RI, Kochel KD, Cheung
TC, Yu GL, et al. (1998) LIGHT, a new member of the TNF
superfamily, and lymphotoxin alpha are ligands for herpes-
virus entry mediator. Immunity 8, 21-30.
91. Rossi JF. (2011) Phase I Study of atacicept in rela-
psed/refractory multiple myeloma (MM) and Waldenstrom's
macroglobulinemia. Clin. Lymphoma Myeloma Leuk. 11,
136-138.
92. Rossi JF, Moreaux J, Hose D, Requirand G, Rose M, Rouille
V, et al. (2009) Atacicept in relapsed/refractory multiple
myeloma or active Waldenstrom's macroglobulinemia: a
phase I study. Br. J. Cancer 101, 1051-1058.
93. Ansell SM, Witzig TE, Inwards DJ, Porrata LF, Ythier A,
Ferrande L, et al. (2008) Phase I clinical study of atacicept in
patients with relapsed and refractory B-cell non-Hodgkin's
lymphoma. Clin. Cancer Res. 14, 1105-1110.
94. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weis-
man M, Kavanaugh A, et al. (2007) Reduced B lymphocyte
and immunoglobulin levels after atacicept treatment in
patients with systemic lupus erythematosus: results of a
multicenter, phase Ib, double-blind, placebo-controlled,
dose-escalating trial. Arthritis Rheum. 56, 4142-4150.
95. Tenhumberg S, Waetzig GH, Chalaris A, Rabe B, Seegert D,
Scheller J, et al. (2008) Structure-guided optimization of the
Search WWH ::
Custom Search